Modeling Efficacy of Bevacizumab Treatment for Metastatic Colon Cancer

Purpose: Bevacizumab, an FDA-approved adjuvant treatment for metastatic colon cancer, has extended survival for many patients. However, factors predicting response to treatment remain undefined. Patients and Methods: Relevant clinical and environmental data were abstracted from medical records of 14...

Descripción completa

Detalles Bibliográficos
Autores principales: Islam, Rezwan, Chyou, Po-Huang, Burmester, James K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654489/
https://www.ncbi.nlm.nih.gov/pubmed/23678369
http://dx.doi.org/10.7150/jca.6083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654489/
https://www.ncbi.nlm.nih.gov/pubmed/23678369
http://dx.doi.org/10.7150/jca.6083

Ejemplares similares